keine Finanzberatung

JNJ · Johnson & Johnson

Diversified pharma and medtech giant, 60+ years of dividend increases

Risiko 3/10 · LOW-MODERATE RISK · healthcare stalwart · $275.23 ▼ 1.15%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $275.23
  • Market cap $663.3B
  • P/E (ttm) 31.97
  • Div yield 1.95%
  • 52-wk range $173.33 – $281.07
  • Index rank #18 / —

Wichtigste Risiken

  • Talc litigation drags on without a final settlement (Shareholders) — MED
  • Stelara biosimilar erosion eats a blockbuster (Shareholders) — MED
  • Pipeline must keep refilling the patent cliff (Shareholders) — LOW
  • US drug-pricing policy squeezes margins (Shareholders) — LOW

Fazit

A sleep-at-night compounder whose known problems are priced in and survivable.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.